secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-057785
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q3 net loss $55.4M; cash $312.8M providing runway into 2026
------------------------------------------------------------------------------

- Net loss of $55.4M for Q3 2023 vs $35.1M in Q3 2022; R&D expenses $50.1M (up 67% YoY).
- Cash, cash equivalents and marketable securities $312.8M as of Sept 30, 2023, down from $350.9M at June 30, 2023.
- SUMMIT NonAdvSM trial Part 1 enrollment completed at 54 patients; Part 2 registration-directed trial to begin 1H 2024.
- APEX AdvSM trial Part 2 enrollment on track to complete by end 2024; SUMMIT Part 1a data selected for oral presentation at ASH 2023.
- PEAK Phase 3 GIST study lead-in data shows 33% ORR in 2nd-line; Phase 3 enrollment on track by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023057785/0000950170-23-057785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023057785/cogt-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer